Announcements Trials

Browse Landscape

Phase

Phase EARLY_PHASE1 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3 Other hematologic neoplasm 3 Head & Neck 2 CNS 2 Tumor-Agnostic 1 Genitourinary 1 Dermatologic 1 Breast 1

Conditions

Recurrence 1 Neoplasms 1 Melanoma 1

Interventions

Dacarbazine 27 Nivolumab 26 pembrolizumab 22 Ipilimumab 20 3-ingenyl angelate 11 Interferon-alpha 10 Imiquimod 10 Temozolomide 9 trametinib 8 Vemurafenib 8 Photochemotherapy 8 Aminolevulinic Acid 8 methyl 5-aminolevulinate 7 dabrafenib 7 cemiplimab 7 aldesleukin 7 Introns 7 Surgical Procedures, Operative 6 Radiotherapy 6 Interferon alpha-2 6 Fluorouracil 6 Paclitaxel 5 Melphalan 5 Interleukin-2 5 Cisplatin 5 Chemotherapy, Adjuvant 5 talimogene laherparepvec 4 binimetinib 4 Specimen Handling 4 Opdualag 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Tranexamic Acid × Dermatologic × Clear all

NCT05899465 2025-03-18

PRIME

University of Aarhus

Phase 3 Recruiting

Melanoma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡